Introduction
Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the accumulation of Philadelphia chromosome positive (Ph+) myeloid cells. CML has an estimated incidence of 1 -1.5 per 100000 populations and represents approximately 15% of all leukemias diagnosed in adults with an onset at 40 -50 years of age 1 . CML, a type of myeloproliferative disease, is characterized by the overproduction of both mature and immature myeloid cells causing high levels of white blood cell counts, splenomegaly, weight loss, fatigue and anemia 2 .
Philadelphia chromosome positive (Ph+) myeloid cells are present in more than 90% of CML patients. As a result of balanced reciprocal translocation between the Abelson gene (ABL1) on the long arm of chromosome 9 and the breakpoint cluster region gene (BCR) on the long arm of chromosome 22, t(9;22) (q34;q11), Philadelphia chromosome is formed. BCR-ABL1fusion gene is stirred as a result of such balanced translocation 3 . In different types of leukemia, various sizes of BCR-ABL fusion protein are synthesized. In more than 90% of CML and 30% -35% of acute lymphoblastic leukemia (ALL) patients, a BCR-ABL protein of 210 kDa is noticed. Tyrosine kinase inhibitor, imatinib showed promising success in the treatment of patients with CML but evolution of resistance in CML patients have emerged as a major problem in the recent years. To surmount the resistance noticed with imatinib treatment, other selective TKIs have been created. Second generation TKIs such as dasatinib, nilotinib and busatinib exhibited better performance for the treatment of CML as compared to imatinib 10 . In the face of the development of second generation TKIs, a small percentage of CML patients and a significant number of patients in advanced phase are either initially refractory to TKIs or ultimately develop resistance 10 . Therefore, a significant number of CML patients are now becoming multi-drug resistant and new challenge to manage such patients.
The aim of this review was to present two cases which recently we have envisaged in our setting as well as to evaluate the mechanisms of developing multi-drug resistance in CML patients.
Case 1
A 45-year-old female patient, wife of a corporal of Bangladesh Army, got admitted into a peripheral military hospital, Chittagong, Bangladesh with the complaints of generalized weakness and a small lump in the left side of the abdomen for a period of two months in May 2010. There she was diagnosed as CML, chronic phase on the basis of complete blood count (CBC), blood film findings and bone marrow examination. At that time capsule Hydroxyurea was started and became under control within one month. For better management she was then transferred to a tertiary level military hospital, Dhaka, Bangladesh. In this hospital she underwent all routine laboratory investigations including repeat bone marrow aspiration and examination. Also her bone marrow sample was sent overseas for BCR-ABL fusion gene study which was detected confirming the diagnosis of CML. Then she was given capsule imatinib mesylate (Cap Enlevin) in standard dose (4 capsules daily as a single dose) and advised for follow up with complete blood count every week. After one month, bone marrow examination and analysis of BCR-ABL fusion gene study was performed and found negative. She was advised to continue the capsule enlevin in the same dose and follow up with CBC fortnightly in her nearest peripheral hospital, Chittagong. She was staying well with such medication until November 2014 when her CBC showed moderate anaemia (8.7 g/dl), increasing white blood cell (WBC) [34X10 9 /L] with significant number of blasts (13%), basophils (4%) as well as myelocytes and meta-myelocytes (19%) suggesting the transition to accelerated phase. Again she was transferred to the military hospital, Dhaka where all relevant investigations including BCR-ABL fusion gene study was done and BCR-ABL fusion gene was again detected. After evaluating all investigations, she was confirmed as the case of CML, accelerated phase and was given tablet dasatinib in standard dose and transferred back to her nearest military hospital where she was under close observation of a hematologist. But within two months, her condition deteriorated and transferred to Dhaka again. Now all laboratory investigations were performed and her bone marrow sample was sent overseas to the same laboratory for detection of BCR-ABL mutation study which revealed the presence of mutation in the P-loop of BCR-ABL domain. Other investigations revealed that the patient landed to blast crisis phase. After critical evaluation, she was prescribed with tablet nilotinib in the usual standard dose. Unfortunately she did not respond to this second generation TKIs and within one month she succumbed to death.
Case 2
A 28-year-old young soldier got admitted into military hospital with the complaints of tiredness, fatigue, increased sweating and feverish feeling for the last two weeks. After performing all relevant investigations including bone marrow examination and BCR-ABL fusion gene study, he was diagnosed as CML, chronic phase and started treatment with capsule enliven in usual standard dose. His disease became under control after two months and discharged with the advice of continuing the medicine and performs CBC fortnightly. With this medication, the soldier was continuing well but after six months he again got admitted with marked pallor, bleeding manifestations and fever. His CBC revealed that the patient transited to blast crisis and started with tablet dasatinib immediately as well as bone marrow sample was sent overseas for BCR-ABL gene mutation study. Unfortunately, before getting the results of all relevant investigations including mutation analysis of the BCR-ABL domain, the patient passed away.
Discussion
Tyrosine Kinase inhibitors showed outstanding success in the treatment of CML patients, but the major problem recently encountered by the clinicians is the development of resistance. Two mechanisms, namely BCR-ABL dependent and independent mechanisms, are mainly responsible for MDR CML. These mechanisms include mutations in the TKI binding domain of BCR-ABL (Fig 1) , over expression of BCR-ABL, ATP-binding cassette (ABC) transporters, aberrant ceramide metabolism, inhibition of apoptosis and changes in the expression levels of microRNAs 6 .
Four regions (P-loop, SH-3, SH-2 and A-loop) of the BCR-ABL domain are crucial for effective binding of imatinib. Point mutations in any of these regions either reduce and/ hinder the binding of TKI and the oncogenic BCR-ABL protein leading to the emergence of drug resistance. Among the four sites, P-loop mutation was more commonly found and responsible for 43% of drug resistance in the accelerated and blast crisis phases. Another mechanism of development of imatinib resistance may also be observed when BCR-ABL oncogene is over expressed. These two mechanisms are BCR-ABL dependent (Fig-3) 11 .
BCR-ABL independent mechanisms are ATP binding cassette (ABC) transporters, human organic cation transporters (hOCT1), aberrant ceramide metabolism, inhibition of apoptosis and changes in the expression level of miroRNAs (Fig-3) . ABC transporters are an extremely preserved transmembrane protein family and in the export/import of various substances into or out of the cells in addition to efflux or influx of drugs across organelles and the cell membrane 12 . ABCB1, also known as multi-drug resistance (MDR1) transporter, is one of the well studied ABC transporters that played an important function in imatinib resistance in CML patients by elevating the expression of MDR1 13 . Genetic changes in MDR1 gene causes increased expression of Pglycoprotein efflux pump leading to imatinib resistant 14 .
Human organic cation transporter (hOCT1) is another transmembrane protein that influences the uptake of substances through the cell membrane and imatinib is one the substrate of hOCT1. Lower level of hOCT1 cause reduced intracellular concentration of imatinib, thereby diminishing the drug activity in the cell 15 .
Aberrant ceramide metabolism is also responsible for drug resistance in CML patients. For programmed cell death, ceramide, synthesized in the sphingomyelin pathway, plays an important role. Ceramide synthesis is also stimulated by Fas/CD95 triggered cell death. Sphingosine is synthesized from ceramide by ceramidase and production of sphingosine 1 phosphate (S1P), which has antiapoptotic effect, is mediated by sphingosine kinase (SK) from sphingosine. Therefore, ceramide/ SIP dimer is a tightly regulated process in respect to its antagonistic effects and vital for drug resistance. Accumulation of S1P in the cell promotes imatinib resistance in CML patients by preventing the degradation of BCR-ABL protein 16 . 
Conclusion
Chronic myeloid leukemia is a highly investigated type of cancer for the creation of new therapeutic protocol to manage the disease. Various methods such as targeting the signaling pathway, direct protein targeting, nanotechnology and knockout/ knockdown techniques are now coming out as new research areas which will in future focus not only on the development of new drugs but also on drug resistance and its mechanisms culminating a better cure and increase quality of life.
